Table: Taisho Pharmaceutical HD - 9-MTH group results
Feb 9 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2022 Dec 31, 2021 Mar 31, 2023
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 227.67 200.05 303.00
(+13.8 pct) (-6.6 pct) (+13.0 pct)
Operating 23.12 7.13 23.50
(+224.2 pct) (-65.8 pct) (+118.7 pct)
Recurring 29.17 11.49 29.50
(+153.8 pct) (-53.5 pct) (+60.2 pct)
Net 20.90 8.97 19.00
(+132.9 pct) (-37.0 pct) (+44.8 pct)
EPS 254.93 yen 110.43 yen 231.76 yen
EPS Diluted 254.60 yen 110.30 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10